Review



v v mem non essential amino acids solution thermo fisher scientific catalogue no 11140050  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Thermo Fisher v v mem non essential amino acids solution thermo fisher scientific catalogue no 11140050
    V V Mem Non Essential Amino Acids Solution Thermo Fisher Scientific Catalogue No 11140050, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dapt+solution/DAPT/pm36655405-292-27-33
    Average 95 stars, based on 1 article reviews
    v v mem non essential amino acids solution thermo fisher scientific catalogue no 11140050 - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: Pump-less, recirculating organ-on-a-chip (rOoC) platform.
    Article Snippet: After formation of spheroids at day 13, media was replaced with William's E media, supplemented with 5% (v/v) FBS, 20 ng ml−1 HGF and 10 ng ml−1 oncostatin M (Peprotech, catalogue no. 300-10), 1% (v/v) ITS, 100 μM AAP, 0.1 μM dexamethasone. .. For further maturation, organoids were cultured in microwells in William's E media, supplemented with 1% (v/v) ITS, 0.1 μM Dexamethasone, 20 ng ml−1 oncostatin M and 1% (v/v) MEM non-essential amino acids solution (Thermo Fisher Scientific, catalogue no. 11140050), 10 uM DAPT for another 10 days with the replacement of media every 48 h. On day 18, organoids were additionally incubated for 1 h in the same medium supplemented with 5% (v/v) of Geltrex. ..

    Incubation:

    Article Title: Pump-less, recirculating organ-on-a-chip (rOoC) platform.
    Article Snippet: After formation of spheroids at day 13, media was replaced with William's E media, supplemented with 5% (v/v) FBS, 20 ng ml−1 HGF and 10 ng ml−1 oncostatin M (Peprotech, catalogue no. 300-10), 1% (v/v) ITS, 100 μM AAP, 0.1 μM dexamethasone. .. For further maturation, organoids were cultured in microwells in William's E media, supplemented with 1% (v/v) ITS, 0.1 μM Dexamethasone, 20 ng ml−1 oncostatin M and 1% (v/v) MEM non-essential amino acids solution (Thermo Fisher Scientific, catalogue no. 11140050), 10 uM DAPT for another 10 days with the replacement of media every 48 h. On day 18, organoids were additionally incubated for 1 h in the same medium supplemented with 5% (v/v) of Geltrex. ..



    Similar Products

    95
    MedChemExpress dapt solution
    Dapt Solution, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dapt+solution/DAPT/pm40341648-127-7-9
    Average 95 stars, based on 1 article reviews
    dapt solution - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    90
    Millipore γ-secretase inhibitor dapt solution
    γ Secretase Inhibitor Dapt Solution, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dapt+solution/dapt/pmc10869796-352-3-7
    Average 90 stars, based on 1 article reviews
    γ-secretase inhibitor dapt solution - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    96
    Selleck Chemicals dmso working solution
    Dmso Working Solution, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dapt+solution/DAPT/pm37056149-49-20-25
    Average 96 stars, based on 1 article reviews
    dmso working solution - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    90
    FUJIFILM dapt solution
    The improvement of mitochondrial abnormalities in MFN2-deficient human iPS cells treated with gamma-secretase inhibitor <t>DAPT.</t> (A) Mitochondrial morphology visualized by MitoTracker in MFN2-deficient human iPS cells with or without <t>50µM</t> of DAPT. (Right panels; magnified area outlined in right panels), Scale bars; 50 µm. (B) Relative transcription levels of HES1 and HEY1 in MFN2-deficient human iPS cells with or without DAPT. (C) MAM visualization in MFN2-deficient human iPS cells, with or without DAPT. (Red; MAM (IP3R-VDAC1 PLA), blue; DAPI, Scale bars; 20 µm. (D) The quantitative analyses of MAM numbers in MFN2-deficient human iPS cells with or without DAPT. (E) Total ATP production in MFN2-deficient human iPS cells treated with or without DAPT. All error bars indicate ±SEM (n=5). P -values are determined by non-parametric Wilcoxon tests for comparisons. *P<0.05.
    Dapt Solution, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dapt+solution/dapt/bio_rxiv__2023__07__19__549786-186-12-18
    Average 90 stars, based on 1 article reviews
    dapt solution - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    96
    Selleck Chemicals dapt working solution
    The improvement of mitochondrial abnormalities in MFN2-deficient human iPS cells treated with gamma-secretase inhibitor <t>DAPT.</t> (A) Mitochondrial morphology visualized by MitoTracker in MFN2-deficient human iPS cells with or without <t>50µM</t> of DAPT. (Right panels; magnified area outlined in right panels), Scale bars; 50 µm. (B) Relative transcription levels of HES1 and HEY1 in MFN2-deficient human iPS cells with or without DAPT. (C) MAM visualization in MFN2-deficient human iPS cells, with or without DAPT. (Red; MAM (IP3R-VDAC1 PLA), blue; DAPI, Scale bars; 20 µm. (D) The quantitative analyses of MAM numbers in MFN2-deficient human iPS cells with or without DAPT. (E) Total ATP production in MFN2-deficient human iPS cells treated with or without DAPT. All error bars indicate ±SEM (n=5). P -values are determined by non-parametric Wilcoxon tests for comparisons. *P<0.05.
    Dapt Working Solution, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dapt+solution/DAPT/pm37083721-51-1-12
    Average 96 stars, based on 1 article reviews
    dapt working solution - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    95
    Thermo Fisher v v mem non essential amino acids solution thermo fisher scientific catalogue no 11140050
    The improvement of mitochondrial abnormalities in MFN2-deficient human iPS cells treated with gamma-secretase inhibitor <t>DAPT.</t> (A) Mitochondrial morphology visualized by MitoTracker in MFN2-deficient human iPS cells with or without <t>50µM</t> of DAPT. (Right panels; magnified area outlined in right panels), Scale bars; 50 µm. (B) Relative transcription levels of HES1 and HEY1 in MFN2-deficient human iPS cells with or without DAPT. (C) MAM visualization in MFN2-deficient human iPS cells, with or without DAPT. (Red; MAM (IP3R-VDAC1 PLA), blue; DAPI, Scale bars; 20 µm. (D) The quantitative analyses of MAM numbers in MFN2-deficient human iPS cells with or without DAPT. (E) Total ATP production in MFN2-deficient human iPS cells treated with or without DAPT. All error bars indicate ±SEM (n=5). P -values are determined by non-parametric Wilcoxon tests for comparisons. *P<0.05.
    V V Mem Non Essential Amino Acids Solution Thermo Fisher Scientific Catalogue No 11140050, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dapt+solution/DAPT/pm36655405-292-27-33
    Average 95 stars, based on 1 article reviews
    v v mem non essential amino acids solution thermo fisher scientific catalogue no 11140050 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    90
    Merck & Co dapt stock solution
    The improvement of mitochondrial abnormalities in MFN2-deficient human iPS cells treated with gamma-secretase inhibitor <t>DAPT.</t> (A) Mitochondrial morphology visualized by MitoTracker in MFN2-deficient human iPS cells with or without <t>50µM</t> of DAPT. (Right panels; magnified area outlined in right panels), Scale bars; 50 µm. (B) Relative transcription levels of HES1 and HEY1 in MFN2-deficient human iPS cells with or without DAPT. (C) MAM visualization in MFN2-deficient human iPS cells, with or without DAPT. (Red; MAM (IP3R-VDAC1 PLA), blue; DAPI, Scale bars; 20 µm. (D) The quantitative analyses of MAM numbers in MFN2-deficient human iPS cells with or without DAPT. (E) Total ATP production in MFN2-deficient human iPS cells treated with or without DAPT. All error bars indicate ±SEM (n=5). P -values are determined by non-parametric Wilcoxon tests for comparisons. *P<0.05.
    Dapt Stock Solution, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dapt+solution/dapt/pm35477753-482-0-5
    Average 90 stars, based on 1 article reviews
    dapt stock solution - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Cayman Chemical dapt solution
    The improvement of mitochondrial abnormalities in MFN2-deficient human iPS cells treated with gamma-secretase inhibitor <t>DAPT.</t> (A) Mitochondrial morphology visualized by MitoTracker in MFN2-deficient human iPS cells with or without <t>50µM</t> of DAPT. (Right panels; magnified area outlined in right panels), Scale bars; 50 µm. (B) Relative transcription levels of HES1 and HEY1 in MFN2-deficient human iPS cells with or without DAPT. (C) MAM visualization in MFN2-deficient human iPS cells, with or without DAPT. (Red; MAM (IP3R-VDAC1 PLA), blue; DAPI, Scale bars; 20 µm. (D) The quantitative analyses of MAM numbers in MFN2-deficient human iPS cells with or without DAPT. (E) Total ATP production in MFN2-deficient human iPS cells treated with or without DAPT. All error bars indicate ±SEM (n=5). P -values are determined by non-parametric Wilcoxon tests for comparisons. *P<0.05.
    Dapt Solution, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dapt+solution/dapt/pmc08355240-475-4-42
    Average 90 stars, based on 1 article reviews
    dapt solution - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    The improvement of mitochondrial abnormalities in MFN2-deficient human iPS cells treated with gamma-secretase inhibitor DAPT. (A) Mitochondrial morphology visualized by MitoTracker in MFN2-deficient human iPS cells with or without 50µM of DAPT. (Right panels; magnified area outlined in right panels), Scale bars; 50 µm. (B) Relative transcription levels of HES1 and HEY1 in MFN2-deficient human iPS cells with or without DAPT. (C) MAM visualization in MFN2-deficient human iPS cells, with or without DAPT. (Red; MAM (IP3R-VDAC1 PLA), blue; DAPI, Scale bars; 20 µm. (D) The quantitative analyses of MAM numbers in MFN2-deficient human iPS cells with or without DAPT. (E) Total ATP production in MFN2-deficient human iPS cells treated with or without DAPT. All error bars indicate ±SEM (n=5). P -values are determined by non-parametric Wilcoxon tests for comparisons. *P<0.05.

    Journal: bioRxiv

    Article Title: The reciprocal regulation between mitochondrial-associated membranes and Notch signaling in skeletal muscle atrophy

    doi: 10.1101/2023.07.19.549786

    Figure Lengend Snippet: The improvement of mitochondrial abnormalities in MFN2-deficient human iPS cells treated with gamma-secretase inhibitor DAPT. (A) Mitochondrial morphology visualized by MitoTracker in MFN2-deficient human iPS cells with or without 50µM of DAPT. (Right panels; magnified area outlined in right panels), Scale bars; 50 µm. (B) Relative transcription levels of HES1 and HEY1 in MFN2-deficient human iPS cells with or without DAPT. (C) MAM visualization in MFN2-deficient human iPS cells, with or without DAPT. (Red; MAM (IP3R-VDAC1 PLA), blue; DAPI, Scale bars; 20 µm. (D) The quantitative analyses of MAM numbers in MFN2-deficient human iPS cells with or without DAPT. (E) Total ATP production in MFN2-deficient human iPS cells treated with or without DAPT. All error bars indicate ±SEM (n=5). P -values are determined by non-parametric Wilcoxon tests for comparisons. *P<0.05.

    Article Snippet: TA muscle was removed 2 weeks after transplantation with several injections of DAPT solution (20µL of 50µM stock, WAKO) as shown in , fixed, and stained as above.

    Techniques:

    The regenerative capacity of Mfn2-deficient mouse muscle is reduced and that of Mfn2-deficient muscle stem cells when transplanted into Dystrophic muscle in vivo is improved by DAPT treatment of the muscle. (A) The flowchart to isolate muscle stem cells (MuSCs, SM-C/2.6+) and non-myogenic fibroblasts (FBs) derived from conditionally Mfn2 knockout mice after 4-OH tamoxifen (4-OHT) injection. (B) Immunostaining for Mfn2 (Green), Myogenin (Myog; Red), and DAPI (blue) on differentiated myotubes derived from wildtype or Mfn2-deficient mouse muscle stem cells sorted as SM-C/2.6 positive cells, co-cultured with non-myogenic fibroblasts (FBs). Scale bar; 50 µm. (C) Phase contrast images (left panels) and MAMs visualization (right panels) and quantitative analyses of MAM numbers (right) on cultured muscle stem cells. (Red; MAM (IP3R-VDAC1 PLA), blue; DAPI, Scale bars; 20 µm. (D) Western Blotting analyses of lysates from control and Mfn2-mutant cultured muscle stem cells. Nuclear lysates were analyzed with antibodies against NICD. Histone H3 was used as a loading control. (E) The flowchart for the transplantation into tibialis anterior (TA) muscles of DMD -/y mice (12 weeks old) with Mfn2-deficient muscle stem cells (1.0 x 10 4 cells) and the treatment with DAPT every 3∼4 days after the transplantation. (F) Transverse sectional images of TA muscles 14 days after the transplantation with the same number of muscle stem cells sorted as SM/C-2.6-positive cells derived from wildtype or conditional Mfn2 Knockout mice. Immunostaining for Dystrophin (Dmd, red as transplanted areas), laminin-a2 (Lama2, white to show the outline of myofibers), and DAPI (blue) on engrafted TA muscle after the transplantation. Scale bars; 50 µm. (G) The quantification of the total number of Dystrophin-positive (Dmd+) regenerated myofibers on the section transplanted with an equivalent number of normal or Mfn2-deficient MuSCs, with or without the treatment of the transplanted muscle with DAPT. (H) The average diameter of Dystrophin-positive (Dmd+) myofibers that are contributed by the transplanted MuSCs, as described in (G). All error bars indicate ±SEM (n=5). P -values are determined by non-parametric Wilcoxon tests or one-way ANOVA and Tukey’s test for comparisons. *P<0.05.

    Journal: bioRxiv

    Article Title: The reciprocal regulation between mitochondrial-associated membranes and Notch signaling in skeletal muscle atrophy

    doi: 10.1101/2023.07.19.549786

    Figure Lengend Snippet: The regenerative capacity of Mfn2-deficient mouse muscle is reduced and that of Mfn2-deficient muscle stem cells when transplanted into Dystrophic muscle in vivo is improved by DAPT treatment of the muscle. (A) The flowchart to isolate muscle stem cells (MuSCs, SM-C/2.6+) and non-myogenic fibroblasts (FBs) derived from conditionally Mfn2 knockout mice after 4-OH tamoxifen (4-OHT) injection. (B) Immunostaining for Mfn2 (Green), Myogenin (Myog; Red), and DAPI (blue) on differentiated myotubes derived from wildtype or Mfn2-deficient mouse muscle stem cells sorted as SM-C/2.6 positive cells, co-cultured with non-myogenic fibroblasts (FBs). Scale bar; 50 µm. (C) Phase contrast images (left panels) and MAMs visualization (right panels) and quantitative analyses of MAM numbers (right) on cultured muscle stem cells. (Red; MAM (IP3R-VDAC1 PLA), blue; DAPI, Scale bars; 20 µm. (D) Western Blotting analyses of lysates from control and Mfn2-mutant cultured muscle stem cells. Nuclear lysates were analyzed with antibodies against NICD. Histone H3 was used as a loading control. (E) The flowchart for the transplantation into tibialis anterior (TA) muscles of DMD -/y mice (12 weeks old) with Mfn2-deficient muscle stem cells (1.0 x 10 4 cells) and the treatment with DAPT every 3∼4 days after the transplantation. (F) Transverse sectional images of TA muscles 14 days after the transplantation with the same number of muscle stem cells sorted as SM/C-2.6-positive cells derived from wildtype or conditional Mfn2 Knockout mice. Immunostaining for Dystrophin (Dmd, red as transplanted areas), laminin-a2 (Lama2, white to show the outline of myofibers), and DAPI (blue) on engrafted TA muscle after the transplantation. Scale bars; 50 µm. (G) The quantification of the total number of Dystrophin-positive (Dmd+) regenerated myofibers on the section transplanted with an equivalent number of normal or Mfn2-deficient MuSCs, with or without the treatment of the transplanted muscle with DAPT. (H) The average diameter of Dystrophin-positive (Dmd+) myofibers that are contributed by the transplanted MuSCs, as described in (G). All error bars indicate ±SEM (n=5). P -values are determined by non-parametric Wilcoxon tests or one-way ANOVA and Tukey’s test for comparisons. *P<0.05.

    Article Snippet: TA muscle was removed 2 weeks after transplantation with several injections of DAPT solution (20µL of 50µM stock, WAKO) as shown in , fixed, and stained as above.

    Techniques: In Vivo, Derivative Assay, Knock-Out, Injection, Immunostaining, Cell Culture, Western Blot, Mutagenesis, Transplantation Assay